Edgewise Therapeutics announced the appointment of Kirsten L. Gruis, M.D., M.S. to the newly created position of Chief Medical Officer. Dr. Gruis will be responsible for leading clinical, medical and regulatory strategy and operations for the drug pipeline, including EDG-5506, the company’s lead product candidate that is being prepared for clinical development for Duchenne and Becker muscular dystrophy (DMD and BMD). Prior to joining Edgewise, Dr. Gruis was Global Head of the neuromuscular franchise at Roche leading the development of SMA and DMD therapeutics.